Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sucampo Pharma Europe

- PMLiVE

The future shape of pharmacy

Change is needed, particularly when it comes to commissioning, leadership and collaborative working

- PMLiVE

First Cymbalta generics approved in the US

Lilly prepares for onslaught of competition for antidepressant

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

- PMLiVE

Survey to gauge impact of doctor-patient talks in diabetes

Lilly and Boehringer sponsor worldwide study

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

Daiichi Sankyo logo

Daiichi Sankyo says meets targets in AF study

Edoxaban on course to add to next generation anticoagulants to replace warfarin

- PMLiVE

Pfizer extends optimisation campaign

Pharma company supports efforts to ensure public get best out of medicines

Eli Lilly HQ

Lilly exploring diabetes portfolio for Alzheimer’s potential

Undertakes pre-clinical investigations as it monitors the area

- PMLiVE

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links